July 19th 2025
Patients with nonmetastatic esophageal cancer who received FLOT chemotherapy achieved a 3-year OS rate of 61.1% in an analysis of the phase 3 ESOPEC trial.
Tiragolumab Combo Improves PFS/OS Vs Chemo in Esophageal Cancer
January 20th 2024Data from the phase 3 SKYSCRAPER-08 trial may support tiragolumab plus atezolizumab and chemotherapy as an alternative frontline treatment option for those with locally advanced or metastatic esophageal squamous cell carcinoma.
Lenvatinib Combo Demonstrates Safety, Activity in Metastatic ESCC
October 23rd 2023Investigators will continue to assess the efficacy and safety of lenvatinib plus pembrolizumab and chemotherapy as frontline treatment for patients with metastatic esophageal squamous cell carcinoma in part 2 of the LEAP-014 study.
Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Tislelizumab/Chemo Yields Survival Benefit in Advanced Esophageal Cancer
April 25th 2023Investigators report that patients with advanced or metastatic esophageal squamous cell carcinoma may have superior overall survival benefit following treatment with tislelizumab/chemotherapy vs placebo/chemotherapy.
First-Line Nivolumab Combos Yield Improved OS Vs Chemo Alone in Esophageal Cancer
February 22nd 2022The CheckMate 648 trial found that using a combination of nivolumab and chemotherapy or nivolumab plus ipilimumab vs chemotherapy alone improved survival in advanced esophageal squamous-cell carcinoma.
Pembrolizumab Plus Chemotherapy Combination Improves Survival in Esophageal Squamous Cell Carcinoma
September 21st 2021Pembrolizumab plus chemotherapy compared with the placebo plus chemotherapy demonstrated an improvement in overall survival and progression-free survival for patients with esophageal squamous cell carcinoma.